Condition: IBD · Ulcerative Colitis · Crohn Disease · Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
This is a French prospective longitudinal observational multicentre cohort study. Primary objective : to assess prospectively the presence and the extent of safety concerns (cancer, serious infections, arterial and venous thrombotic events) in patients with CD and UC and treated with JAKi, anti-IL23p19, and S1p modulators.
This description comes directly from the study's public registry record.
Marie Coisnon · 09 72 57 61 60 · mcoisnon@getaid.org
Charlotte Mailhat · 09 72 57 61 60 · cmailhat@getaid.org
Always discuss trial participation with your own doctor first.
| CHU Amiens Picardie | Amiens, France | Recruiting |
| APHP Hôpital Saint Antoine | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06089590